![]() |
市場調查報告書
商品編碼
1125336
全球精神分裂症藥物市場規模調查,按治療類別、療法、分銷渠道和地區預測 2022-2028Global Schizophrenia Drugs Market Size study, By Therapeutic Class, By Treatment, By Distribution Channel, and Regional Forecasts 2022-2028 |
精神分裂症是一種嚴重的精神疾病,會導致對現實的異常解釋。
精神分裂症會引起幻覺和妄想、思想和行動障礙、言語和行為障礙、思維障礙、缺乏動力等各種症狀,並干擾日常生活。精神分裂症患病率的上升、對心理健康的認識不斷提高以及大公司的戰略舉措是推動全球市場需求的因素。例如,根據世界衛生組織 (WHO) 的估計,截至 2022 年,全球約有 2400 萬人,即每 300 人中有 1 人 (0.32%) 將受到精神分裂症的影響。在成人中,這一比例為 222 分之 1(0.45%)。此外,市場見證了主要市場參與者的多項戰略舉措,包括最近的產品批准和合作夥伴關係,預計這些舉措將影響全球精神分裂症藥物市場的增長。例如,2021 年 9 月,強生公司獲得了美國食品和藥物管理局 (FDA) 對長效非典型抗精神病藥物 INVEGA HAFYERA(棕櫚酸帕利□酮 6 個月)的批准。這種新藥每年註射兩次,用於治療成人精神分裂症。此外,2021 年 11 月,位於英國倫敦的 Sosei Heptares 和位於加利福尼亞州聖地亞哥的 Neurocrine Biosciences 將合作開髮用於精神分裂症和其他神經精神疾病的新型毒蕈鹼受體激動劑。此外,預計人口老齡化的增加以及焦慮和抑鬱的增加也將成為推動預測期內市場需求的因素。然而,缺乏對精神分裂症的認識以及與精神分裂症藥物相關的成癮性上升等阻礙了 2022-2028 年預測期間的市場增長。
全球精神分裂症藥物市場研究考慮的重點地區是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。由於精神障礙發病率的增加和大公司的存在,北美已成為全球市場份額的主要地區。另一方面,預計亞太地區將在 2022-2028 年的預測期內呈現顯著的增長率。醫療保健行業的強勁增長和老年人口不斷增加等因素將為亞太地區的全球精神分裂症治療市場創造良好的增長前景。
本報告中包括的主要市場進入者是:
本研究的目的是確定近年來各個細分市場和國家/地區的市場規模,並預測未來八年的價值。本報告旨在捕捉所研究的每個地區和國家的行業的定性和定量方面。此外,它還提供了有關關鍵方面的詳細信息,例如定義市場未來增長的驅動因素和挑戰。此外,報告還應詳細分析主要參與者的競爭格局和產品供應,以及微觀市場中可供利益相關者投資的機會。市場的詳細細分和子細分如下所述。
按治療類別
第二代
第三代
按治療
口服藥物
注射
按銷售渠道
醫院藥房
零售藥店
網上藥店
按地區
北美
美國
加拿大
歐洲
英國
德國
法國
西班牙
意大利
其他歐洲
亞太地區
中國
印度
日本
澳大利亞
韓國
其他亞太地區
拉丁美洲
巴西
墨西哥
世界其他地方
此外,本研究考慮的年份是:
過去幾年 - 2018 年、2019 年、2020 年
2021 年基準年
預測期 - 2022-2028
本報告的目標受眾是全球精神分裂症藥物市場。
主要諮詢公司和顧問
大公司、中型公司、中小企業
風險投資
增值經銷商 (VAR)
第三方知識提供者
投資銀行家
投資者
Global Schizophrenia Drugs Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028.
Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia results in different conditions such as hallucinations, delusions, disordered thinking and behavior, disorganized speech, trouble with thinking and lack of motivation that impairs daily functioning. The rising in prevalence of Schizophrenia and increasing awareness towards mental health as well as Strategic initiatives from leading market players are factors that are accelerating the global market demand. For instance, according to World Health Organization (WHO) estimates - as of 2022, Schizophrenia affects around 24 million people or 1 in 300 people (0.32%) worldwide. Among adults this rate is 1 in 222 people (0.45%). Furthermore, the market witnessed several strategic initiatives from leading market players including recent product approvals, and partnerships would influence the growth of Global Schizophrenia Drugs market. For instance, in September 2021, Johnson & Johnson received the U.S. Food and Drug Administration (FDA) approval for its long-acting atypical antipsychotic INVEGA HAFYERA (6-month paliperidone palmitate) drug. This new drug is twice-yearly injectable and intended for the treatment of schizophrenia in adults. Moreover, in November 2021, London, UK based Sosei Heptares and San Diego, California, USA based Neurocrine Biosciences entered in a Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders. Also, growing number of geriatric individuals coupled with increasing incidences of anxiety and depression are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, a lack of awareness towards Schizophrenia and increasing incidences of addiction associated with Schizophrenia drugs impede the growth of the market over the forecast period of 2022-2028.
The key regions considered for the global Schizophrenia Drugs Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing incidences of mental disorders and presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as the thriving growth of the healthcare industry and rising geriatric population, would create lucrative growth prospects for the global Schizophrenia Drugs Market across the Asia Pacific region.
Major market players included in this report are:
Pfizer Inc.
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck KGAA
Minerva Neurosciences
Novartis AG
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapeutic Class
Second Generation
Third Generation
By Treatment
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019, 2020
Base year - 2021
Forecast period - 2022 to 2028
Target Audience of the Global Schizophrenia Drugs Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
List of figures